Sandset, E.C., Bath, P.M., Boysen, G., Jatuzis, D., Korv, J., Luders, S., Murray, G.D., Richter, P.S., Roine, R.O., Terent, A., Thijs, V., Berge, E. and Group, S.S. (2011) The Angiotensin-Receptor Blocker Candesartan for Treatment of Acute Stroke (SCAST): A Randomised, Placebo-Controlled, Double-Blind Trial. The Lancet, 377, 741-750.

has been cited by the following article:

• TITLE: Interaction between Antihypertensive Therapy Class and Pulse Pressure on Outcomes Following Acute Ischemic Stroke

  AUTHORS: Michael Lavelle, Roy O. Mathew, Jaspreet Arora, Avinash Murthy, Le Du, Batyrjan Bulibek, Mandeep Sidhu, Mikhail Torosoff

  KEYWORDS: Acute Ischemic Stroke, Pulse Pressure, Angiotensin Blockers, Beta Blockers, Outcomes

  JOURNAL NAME: International Journal of Clinical Medicine, Vol.8 No.10, October 17, 2017

  ABSTRACT: Goal: The effect of pulse pressure and interactions with type of antihypertensive therapy on mortality after acute ischemic stroke has not been previously evaluated. Materials and Methods: A retrospective cohort study was conducted to evaluate the independent and interactive effects of pulse pressure and antihypertensive class (specifically angiotensin converting enzyme inhibitor/angiotensin type 1 receptor blocker, or beta blocker) on mortality following acute ischemic stroke. Findings/Conclusions: 343 patients were identified with 49 months of follow-up. Baseline pulse pressure was 64 mmHg and age was 66.5 years. Patients were divided at a pulse pressure of 70. Patients with pulse pressure ≥ 70 were older (p